HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th
July 13 2022 - 2:03PM
HeartSciences (NASDAQ: HSCS; HSCSW) (“Company”), a medical
technology company focused on applying innovative AI-based
technology to an ECG (also known as an EKG) to significantly expand
and improve an ECG’s clinical usefulness, today announced that
Andrew Simpson, CEO, and Chairman of HeartSciences, will be
participating in the Benzinga All Access event taking place on July
15, 2022.
Mr. Simpson is scheduled to present on Friday,
July 15, 2022, at 10:00 A.M. Eastern Time.
The event will be broadcast live and can be
viewed
https://www.youtube.com/watch?v=JuM_q3iRTeM&feature=youtu.be.
An archived recording of the presentation will be available on the
investor relations section of the Company’s website at
https://ir.heartsciences.com/.
About Benzinga All Access
Benzinga All Access is a first-of-its-kind show:
part interview, part investor presentation. On All Access, Benzinga
partners with companies to bring you in-depth one-on-one
conversations with executives across a wide range of industries and
asset classes. From emerging biotechs, to alternative real estate
investment platforms, to everything in between, guests on All
Access have one thing in common: they want to tell their story to
investors.
About Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. (d/b/a HeartSciences) is medical
technology company focused on applying innovative AI-based
technology to an ECG (also known as an EKG) to expand and improve
an ECG’s clinical usefulness. The Company’s objective is to make an
ECG a far more valuable cardiac screening tool, particularly in
frontline or point-of-care clinical settings. HeartSciences’ first
product candidate for FDA clearance, the MyoVista wavECG, or the
MyoVista, is a resting 12-lead ECG that is also designed to provide
diagnostic information related to cardiac dysfunction which has
traditionally only been available through the use of cardiac
imaging. The MyoVista also provides conventional ECG information in
the same test. The business model, which involves the use of the
MyoVista device and consumables for each test, is expected to be
“razor-razorblade” as the electrodes used with the MyoVista are
proprietary to HeartSciences, and new electrodes are required for
every test performed. Additional information about the
Company is available at www.heartsciences.com.
Important Cautions Regarding Forward Looking
Statements
This press release contains certain "forward-looking statements"
within the meaning of federal securities laws. All statements,
other than statements of historical facts, included herein are
"forward-looking statements" including, among other things,
statements about HeartSciences’ beliefs and expectations. The
expectations reflected in these forward-looking statements involve
significant assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Potential risks and
uncertainties include, but are not limited to, risks discussed in
HeartSciences’ filings with the U.S. Securities and Exchange
Commission at www.sec.gov. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
Contact:
Crescendo Communications, LLC Email: HSCS@crescendo-ir.com Tel:
(212) 671-1021
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Sep 2023 to Sep 2024